Willowglade Technologies has developed a centralized, patient-centric IT platform called the Personalized Patient Experience Platform to improve care coordination and patient engagement. The platform provides tools to keep patients informed and connected throughout their care and allows providers to better monitor patients. It addresses the current fragmented and provider-focused nature of healthcare by placing the patient at the center of the care coordination process. The company is raising $1.25 million to further develop the platform and expand sales and marketing efforts to target the growing markets for chronic condition management and oncology care, where their platform could qualify for CMS reimbursement and help reduce healthcare costs.

1. Investment Brief February 2016
WillowgladeTechnologies
Corporation

2. Willowglade Technologies
Investment Brief 2
Overview
Patients are faced with all types of medical conditions
and diseases and have to navigate a complex
landscape of educational, appointment, medication and
logistical needs. As conditions become more complex,
interactions with the healthcare system become more
confusing to the patient.
Depending on the condition, care coordination can
involve:
—— Primary care
—— Specialty care
—— Inpatient care
—— Mental health services
—— Long-term care
—— Medical history
—— Test results
—— Home care
—— Patient/family education & support
—— Medications/pharmacy
—— Community resources
Care coordination software and related technologies
are a growth market, including IT applications for
team-based patient care and for patients transitioning
between care settings. Payers hope to provide better
data for predictive analytics needed to drive population
health programs. Hospitals expect improvement in
patient care and to avoid financial penalties associated
with federal mandates, in addition to higher patient
satisfaction scores and competitiveness. Physicians
want to close information gaps and loopholes, in
addition to improving quality of care and creating new
revenue streams from opportunities such as chronic
condition management.
However, even where technology is leveraged, solutions
are provider-focused and neglect the importance of
patient engagement in the care coordination process.
Nurses use spreadsheets to track patients.They
communicate by phone. Multiple providers are often
involved in care coordination and technologies in
the market today fail to efficiently coordinating these
activities. Setting appointments and tracking follow-ups
with patients and professionals involved in each case
can become difficult to manage effectively.The quality
of care erodes. Meanwhile, the patient is not adequately
engaged.
Patients want to be engaged.
They want to understand their
treatment and related options.
WillowgladeTechnologies has developed a centralized
IT platform which is patient-centric, enabling the patient
to inform and participate in their own care coordination
process.
In addition to providing a means of coordinating
disparate care related activities so that providers
involved in a patient’s care can share important clinical
information and have clear, shared expectations about
their roles in care, Willowglade’s Personalized Patient
Experience Platform deepens the care coordination
paradigm by engaging the patient and placing the
patient at the center of the process.
It provides tools and resources to keep patients and
families informed, connected and to optimize their
experience throughout the care process, and it provides
tools for the care team to monitor, understand patient
progress and engage with the patient when they are not
directly within the walls of the health system.

3. Willowglade Technologies
Investment Brief 3
In order to advance care and improve health outcomes,
patients need to be engaged in their own health and
with their physicians and other care providers. People
are invested in and want to be engaged with their health
and wellness as long as they can trust the source of the
information and engage and be supported by a care
team member.
The WillowgladeTechnologies platform is designed
to support this dramatically enhanced level of patient
involvement.
SPECIALTY CARE
INPATIENT CARE
MENTAL HEALTH
SERVICES
LONG TERM CARE
MEDICAL HISTORY
PRIMARY CARE
COMMUNITY RESOURCES
PATIENT/FAMILY
EDUCATION & SUPPORT
HOME CARE
WE PLACE THE PATIENT AT THE CENTER
OF THE HEALTHCARE CONTINUUM.
TEST RESULTS

4. Willowglade Technologies
Investment Brief 4
Personalized Health Navigator
(patient interaction)
Health Orchestrator
(healthcare professional interaction)
Personalized Patient Experience Platform
(Orchestration Engine, technical platform, HIPAA compliant cloud,
tailored for each client use/case, content management, facilitates data analysis)
Personalized Health Navigator Benefits Health Orchestrator Benefits
—— Improved communication with
care givers, friends & family
—— Addresses each patient’s specific social,
emotional or clinical issues & concerns
—— Allows documentation & review of medication
—— Alerts & reminders to the patient’s
condition & situation
—— Patients can record clinical data &
information directly into the mobile app
—— Data collection from remote monitoring
devices/wearables provides time efficiency
for both the patient & clinician
—— Accessible information on progress to
patient & clinicians for monitoring
—— Data entered by patient is reviewed,
analyzed & acted on by care team
members in Health Orchestrator
—— Ability to orchestrate and communicate care more
efficiently to multiple outlets through one platform
(social worker, clinician, physical therapists & more)
—— CMS reimbursement opportunities
—— Accessibility to large population management
under one platform: Health Orchestrator
—— Effortless data collection from home
through remote monitoring
—— Time efficient for both the clinician and patient
Personalized Patient Experience Platform Benefits
—— Ability to communicate more efficiently to multiple outlets through one
platform (social worker, clinician, physical therapists & more)
—— CMS reimbursement opportunities
—— Accessibility to large population management under one platform: Health Orchestrator
—— Effortless data collection from home through remote monitoring
—— Time efficient for both the clinician & patient

5. Willowglade Technologies
Investment Brief 5
Capitalization and Offering
We are raising up to $1,250,000 in common stock, which
will be used to further development of our technology
platform, retention of key employees, ramping of sales
and marketing efforts and general working capital
purposes.
Pro Forma Capitalization Pre-Offering Post-Offering
Shares Out % of Out Shares Out % of Out
Founders 7,250,000 77.4% 7,250,000 68.3%
Other Shareholders (options) 805,500 8.6% 805,500 7.6%
2013 Option Plan Reserved for Issuance 1,194,500 12.8% 1,194,500 11.3%
Other Shareholders (debt conversion) 116,430 1.2% 116,430 1.1%
New Shareholders (Current Offering) - 0.0% 1,250,000 11.8%
Total 9,366,430 100.0% 10,616,430 100.0%
Key Offering Data Max
Shares Authorized 12,000,000
Shares Out 9,366,430
Shares Issued 8,171,930
2013 Stock Option Plan 2,000,000
Warrants/Options Out 805,500
Convertible Debt $287,825
Shares issued on Debt Conv. 366,430
Shares Out Fully Diluted 9,366,430
Offering $1,250,000
Offering Price/Share $1.00
Offered Shares 1,250,000
Post Offering Shares Out (FD) 10,616,430
Post Offering Valuation $10,616,430
Use of Proceeds Max
Research and Development $250,000
Marketing and Sales 400,000
Operations 600,000
Gross Proceeds 1,250,000
Offering Expenses $87,500
Net Proceeds $1,162,500

6. Willowglade Technologies
Investment Brief 6
Market Overview and Key Themes
We believe our market opportunity is massive and
growing. Baby boomers are turning 65 at a rate of
nearly 10,000 individuals a day. Over the next five years,
17 million baby boomers will turn 65. More people
are retiring, joining the Medicare system, developing
chronic health conditions, including cancer and needing
more care as they age.
Our services are focused on the oncology and
chronic health care market.The health care industry
is complex, disconnected and fragmented, and is
largely served by legacy software systems that cannot
support the current needs for collaboration, flexibility
and interoperability. A disproportionate amount of
communication still takes place on paper instead of
via automated communications. Outdated, inflexible
systems and paper workflows create significant costs for
health care organizations, which suffer with substantial
administrative work, duplicated efforts, and errors.
The success of health systems increasingly depend
on their ability to engage patient populations and to
coordinate patient care across a multitude of settings,
while optimizing efficiency along the way.
Competitive Landscape
Our market is quite competitive. However, our primary
competition has traditionally used locally installed
software to manage the various clinical and financial
workflow needs within the medical group or health
system, though more companies are evolving to cloud-
based systems. Companies that we believe are directly
competitive to WillowgladeTechnologies include Care
Merge, CareThread, Health Loop, Navigating Cancer,
Welkin and Well Frame. We believe that our patient-
centered program is a differentiated and superior
approach to patient care and positions our Company
well to compete.Willowglade
CareMerge
CareThread
HealthLoop
Navigating
Cancer
Welkin
WellFrame
Patient Engagement & Care Coordination
Simple Care Coordination
Flexible for many use cases
Engaging CareTeam
Engaging Support Network
Mobile Device Accessibility
ePRO
Generic Education Content
EDC/Medical Devices
Automated Care Coordination
Multi-Language Capable
Patient Messaging & Communication

7. Willowglade Technologies
Investment Brief 7
Chronic Condition Management &
CMS Reimbursement
More than 130 million Americans – one-third of the total
population – suffer from at least one chronic disease.
In addition to the human cost, the financial cost is
staggering. 85% of all healthcare spend goes to the
treatment of chronic diseases, and more than two-thirds
of Medicare dollars are spent on patients with five or
more chronic diseases.
Research studies have demonstrated that care
management reduces total costs of care for chronic
disease patients while improving their overall health.
The Center for Medicare and Medicaid services (CMS)
has introduced new billing (CPT) codes that allow for the
remote management of patients with chronic conditions.
Oncology Care Model and CMS
Reimbursement
Cancer is the second largest cause of death in the U.S.
and related costs of cancer care are $157 billion.1
The
total cost in 2020 is expected to increase to $174 billion.
Each year 650,000 patients in the U.S. receive
chemotherapy in an outpatient oncology clinic2
with
the 65-age and older population having the highest
incidence of diagnosis. Approximately 50% of patients
in oncology practices are Medicare Beneficiaries.The
Center for Medicare and Medicaid Services (CMS)
continues to explore mechanisms to improve quality of
care, while maintaining or improving quality of care and
quality of life indicators.
The goal of CMS is to appropriately align
financial incentives to improve care coordination,
appropriateness of care and access to care for
beneficiaries undergoing chemotherapy treatment.
Research studies have demonstrated that care
management reduces total costs of care for chronic
disease patients while improving their overall health.
The Center for Medicare and Medicaid services (CMS)
has introduced new billing (CPT) codes that allow for the
remote management of patients with chronic conditions.
Note: Based on revenues generated by our customers,
we anticipate a fee of $10/patient/month for both OCM
and CCM models
CMS Economics
(Chronic Condition Management & Oncology Care Management)
For each 500 patients:
Chronic Condition Management Reimbursement perYear: $251,520 ($41.92 per patient/month)
Oncology Care Management Reimbursement perYear: $960,000
($160.00 per patient/month)
1
National Cancer Institute.
2
Centers for Disease Control and Prevention
CPT Code
(CCM & OCM)
CCM (20 minutes/month)
OCM (meet requirements)
Per Patient Per 30-day Period

8. Willowglade Technologies
Investment Brief 8
Our Technology – The Personalized
Patient Experience Platform
The Personalized Patient Experience Platform enables
dramatically enhanced involvement and engagement
of patients that are candidates for Chronic Care
Management, Oncology Care Model programs as well
as transitional care, and cancer navigation programs.
In addition to facilitating programs to guide patients
through the management of their chronic condition, it
facilitates direct capture of electronic patient reported
outcomes, electronic data capture, personalized
educational content delivery on mobile devices to
patients and even the engagement of a patient’s friends
and family in a support network.
Typical Scenario
Client challenges the Personalized Patient
Experience Platform addresses:
—— Non-standardize patient intake
—— Inconsistent collection of quality of life indicators
—— Poor education of patient regarding treatment &
—— treatment options
—— Inability to maintain contact and understand post-
—— treatment outcomes
—— Poor long-term post-treatment
follow-up & monitoring

9. Willowglade Technologies
Investment Brief 9
Health Orchestrator
Health Orchestrator is used by the healthcare team
to interact with and coordinate care for the selected
population of patients. Multiple conditions can be
managed on the same Health Orchestrator platform
simultaneously.
With Health Orchestrator, data captured by patients
directly in their Navigation app or via in-home
medical devices (steps per day, heart rate, blood
pressure or whatever is required to be monitored by
the patient) is available to be viewed and analyzed.
Health Orchestrator also allows for ePRO (Patient
Reported Outcomes) monitoring and analysis so that
case managers have a better understanding of the
actual outcomes that are being achieved (or not) by
each patient in the population they are managing. Of
course, there are a variety of alerting mechanisms that
allow the Case Managers to better understand patient
self-reported outcomes. support groups (friends and
family), in the process of achieving chronic condition
improvement goals.
Features
—— Patient list management
—— Analysis/review of data
—— Patient/care team member assignment
—— Creation of care teams
—— Document care activities
—— Engage other care team members
in care provision
—— Track time spent on care activity
—— Analysis and review of patient reported outcomes
Personalized Health Navigator
Personalized Health Navigator is used by patients to
better understand their treatment and related options.
Using the Navigator app and orchestrator platform
the patient has a way to engage and more effectively
interact, communicate, and engage with the health
system that is using the platform to manage their
case, in addition to a given population of patients.
The Personalized Health Navigator provides
tailored content specific to patient requirements,
on a mobile device, including educational content,
communication and clinical content.The Personalized
Health Navigator not only facilitates data capture
through wearable and other in-home devices, but also
provides a social platform to facilitate communication
with invited support groups (friends and family),
in the process of achieving chronic condition
improvement goals.
Features
—— HIPAA compliant secure cloud
platform with data encryption
—— Dual authentication user accounts using PINs
—— Orchestration Engine facilitates
communication, collaboration, automated
alerts & automated inference on a large
variety of patient & care team inputs
—— CMS housing client specific
—— Data review & analysis

10. Willowglade Technologies
Investment Brief 10
Financial Overview
We are raising up to $1,250,000 in common stock, which
will be used to further development of our technology
platform, retention of key employees, ramping of sales
and marketing efforts and general working capital
purposes.
Pro Forma Income Statement (USD rounded) 2016 2017 2018 2019 2020
Revenue
Initial Installs 250,000 210,000 240,000 240,000 240,000
Ancillary Installs 170,000 880,000 960,000 1,040,000 1,220,000
Patient Subscription Fees (Hospitals) 610,000 2,080,000 3,220,000 5,330,000 6,860,000
Patient Subscription Fees (CC Facilities) 330,000 3,730,000 12,150,000 16,530,000 19,060,000
Communications Modules 70,000 230,000 350,000 570,000 740,000
In-Home Integration 70,000 230,000 350,000 570,000 740,000
Comm. w/ Secure Video 70,000 230,000 350,000 570,000 740,000
Medication Compliance 40,000 120,000 180,000 290,000 370,000
Integration with EMR 30,000 250,000 520,000 790,000 1,060,000
Hosting & Management 20,000 220,000 450,000 670,000 890,000
Total Revenue 1,660,000 8,180,000 18,770,000 26,600,000 31,920,000
Total Direct Costs 100,000 420,000 790,000 1,220,000 1,570,000
Gross Margin 1,560,000 7,760,000 17,980,000 25,380,000 30,350,000
Operating Expenses
Total Sales and Marketing Expenses 240,000 950,000 2,050,000 2,940,000 3,550,000
Total G&A Expenses 1,160,000 1,390,000 1,840,000 2,360,000 2,970,000
Total Operating Expenses 1,400,000 2,340,000 3,890,000 5,300,000 6,520,000
Operating Income (Loss) 160,000 5,420,000 14,090,000 20,080,000 23,830,000
Total Other Income 10,000 20,000 70,000 170,000 300,000
Pre-Tax Profit (Loss) 130,000 5,400,000 14,130,000 20,230,000 24,090,000
IncomeTaxes 20,000 1,840,000 4,830,000 7,070,000 8,420,000
Net Income (Loss) 110,000 3,560,000 9,300,000 13,160,000 15,670,000
EBITDA (Loss) 120,000 5,380,000 14,060,000 20,070,000 23,790,000

11. Willowglade Technologies
Investment Brief 11
Our target customers are hospitals, primary care
(chronic conditions), oncology speciality care and
organization that are part of the Oncology Care Model
program. Our revenue model consists of one-time fees
for deployment and ancillary enhancements to our
platform, and recurring subscription as well as hosting
fees. We are a technology services company and will
remain committed to ongoing development of value-
added services that we can introduce to the market
which will be incremental to our core offering.
We are able to achieve a higher fee structure for Chronic
Care facilities due to CMS reimbursement. In contrast
to the hospital patient fee structure of $0.25 to $1.25 per
patient, we receive a fee of $7.00 to $10.00 per patient in
the Chronic Care business segment. We also anticipate
the same ($10/patient/month) with organizations
engaged with the Oncology Care Model scenario.
Pro Forma Income Statement (USD rounded) 2016 2017 2018 2019 2020
Total Revenue 1,610,000 8,130,000 18,730,000 26,580,000 31,870,000
Total Direct Costs 100,000 420,000 790,000 1,220,000 1,570,000
Gross Margin 1,510,000 7,710,000 17,940,000 25,360,000 30,310,000
Total Operating Expenses 1,390,000 2,340,000 3,880,000 5,300,000 6,520,000
Operating Income (Loss) 120,000 5,380,000 14,060,000 20,070,000 23,790,000
Total Other Income 10,000 20,000 70,000 170,000 300,000
IncomeTaxes 20,000 1,840,000 4,830,000 7,070,000 8,420,000
Net Income (Loss) 120,000 3,570,000 9,300,000 13,170,000 15,670,000
EBITDA (Loss) 120,000 5,380,000 14,060,000 20,070,000 23,790,000
% 7 % 66 % 75 % 76 % 75 %
Total Current Assets 1,500,000 5,120,000 14,470,000 27,740,000 43,470,000
Fixed Assets, Net - - - - -
Total Other Assets - - - - -
Total Assets 1,500,000 5,120,000 14,470,000 27,740,000 43,470,000
Total Current Liabilities 140,000 200,000 260,000 360,000 420,000
Total LongTerm Liabilities - - - - -
Total Equity 1,370,000 4,930,000 14,220,000 27,390,000 43,470,000
Total Liabilities and Equity 1,500,000 5,120,000 14,470,000 27,740,000 43,470,000
Total Cash From (For) Operating Activities -50,000 2,560,000 7,590,000 11,960,000 14,850,000
Total Cash From (For) Investing Activities - - - - -
Total Cash From (For) Financing Activities 1,250,000 - - - -
Net Increase (Decrease) In Cash 1,210,000 2,560,000 7,590,000 11,960,000 14,850,000
Cash and Cash Equivalents-End 1,210,000 3,770,000 11,350,000 23,310,000 38,160,000

12. Willowglade Technologies
Investment Brief 12
John Papandrea, Founder, President and CEO
Beginning his career as a clinical laboratory scientist,
John has an extensive career in healthcare, healthcare IT
and healthcare strategy. John has spent the last 20 years
working in the US and globally assisting healthcare
organizations grow, strategize and leverage technology
to improve processes, financial operations and patient
outcomes. Johns work history includes leadership
roles at Ernst &Young as well as Deloitte Consulting.
Prior to founding Willowglade, John was Senior Vice
President of Health Sciences at SAP, responsible for
the development and execution of SAPs health science
technology strategy globally.
Eric Zothner –Technical Director
With over 15 years of experience in enterprise software
solutions, Eric has authored several patents in applying
analytics and expert rule system to complex systems.
He has worked to transform these systems into
reusable and sustainable technologies using cloud and
mobile innovations. He has expert level knowledge of
enterprise server architectures, mobile technologies,
business intelligence, J2EE, SOA, Iterative and Agile
development methodologies. He has served as an
IT leader at LabCorp and Quintiles. Eric is the chief
architect of the WillowgladeTechnologies platform.
John Powers, Advisor
John is an executive level professional with a proven
track record in wireless and medical technologies,
efficiently developing and deploying business strategies
that drive bottom-line profits. John has global
experience building sales and operations teams and
distributor networks, has strong merger and acquisition
experience and has a track record of establishing and
driving global sales and marketing initiatives.
Patrick Mani, Advisor
Patrick is vice president of corporate and business
channel sales for a global Digital Products Division at
one of the world’s largest PC and device manufacturers.
He is responsible for developing the global sales and
management strategy for both channel and corporate
global business sales.
Carla Balch, Advisor
Carla is focused on bringing 21st Century medicine
and technologies to cancer patients. She is committed
to finding the cutting edge science and technologies
and delivering access to immunotherapy to patients in
the community setting. Serving cancer patients since
1999, Carla joined Altos Solutions in 2007 as President.
Altos made a very successful exit in May 2014 selling to
Google Ventures backed Flatiron Health.
Graham Freckleton
Mr. Freckleton holds a Bachelor of Science degree
in Computing Science from the NSW Institute of
Technology, Sydney, Australia. He has extensive
experience working as a Software Developer and as
a ChiefTechnology Officer in the finance industry He
has experience designing, implementing, developing
and delivery of web applications as well as extensive
experience working as a developer on enterprise
projects. As the finance industry is seen as a leader
in the adaption of technologies, Mr Freckleton brings
leading methods, approaches and innovations to the
Willowglade team.
Gail Lebovic, MD, Advisor
Dr Lebovic is a nationally recognized Oncoplastic Breast
Cancer Surgeon who also is a serial entrepreneur. She
has led 7 successful exits of clinical startup companies,
with all products still in market. She is founder of the
“School of Oncoplastic Surgery” where she dedicates
her talents to assisting other surgeons to understand
and use best practice Oncoplastic surgery techniques.
Dr Lebovic is also a founder and Chief Medical Officer of
FocalTherapeutics, a company dedicated to improving
patients’ lives and cancer therapies with a product she
invented called “Biozorb”.
Management Team & Advisors

13. Willowglade Technologies
Investment Brief 13
Liquidity & Exit Strategy
The digital health sector posted $4.5 billion in total
venture funding in 2015, up from $4.3 billion in 2014.
In total, digital health accounted for 7% of all venture
funding in 2015. 187 M&A deals were consummated,
and $1.4 billion was raised through IPOs to create $8
billion in market capitalization .
Fueled by trends such as the aging population and
rising healthcare costs amidst regulatory uncertainty,
we believe that investor interest and participation in the
digital health sector will remain strong for companies
that can demonstrate viable, scalable solutions designed
to improve care and reduce costs.
As noted above, M&A activity also remains strong. We
expect that as our business gains commercial traction
we will be an attractive acquisition candidate to larger,
more established healthcare firms. In addition, we will
continue to evaluate potential strategies to undertake
an initial public offering onto a national listed exchange
as a means of driving shareholder value and providing
liquidity to our investors.
Disclaimer
This is Not an Offer to Purchase or Sell Securities.This overview is for
informational purposes and is not an offer to sell or a solicitation of an offer
to buy any securities in WillowgladeTechnologies, Inc., and may not be relied
upon in connection with the purchase or sale of any security. Securities of
WillowgladeTechnologies Corporation., if offered, will only be available to
parties who are “accredited investors” (as defined in Rule 501 promulgated
pursuant to the Securities Act of 1933, as amended) and who are interested in
investing in WillowgladeTechnologies Corporation. on their own behalf. Any
offering or solicitation will be made only to qualified prospective investors
pursuant to a confidential offering memorandum, and the subscription
documents, all of which should be read in their entirety.
To obtain further information, you must complete our investor questionnaire
and meet the suitability standards required by law.
Cautionary Note Regarding Forward-Looking Statements/Pursuant to the U.S.
Private Securities Litigation Reform Act of 1995
This investment brief contains, and our officers and representatives may from
time to time make, “forward-looking statements” within the meaning of the safe
harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995.
Forward-looking statements can be identified by words such as: “anticipate,”
“intend,” “plan,” “goal,” “seek,” “believe,” “project,” “estimate,” “expect,”
“strategy,” “future,” “likely,” “may,” “should,” “will” and similar references to
future periods. Examples of forward-looking statements include, among others,
statements we make regarding launch of products, sales, markets, marketing
strategies, our estimates on future financial performance, revenue growth and
earnings, anticipated levels of capital expenditures and our belief that offering
proceeds will provide sufficient liquidity to fund our business operations over
the next 36 months.
Forward-looking statements are neither historical facts nor assurances of future
performance. Instead, they are based only on our current beliefs, expectations
and assumptions regarding the future of our business, future plans and
strategies, projections, anticipated events and trends, the economy and other
future conditions. Because forward-looking statements relate to the future,
they are subject to inherent uncertainties, risks and changes in circumstances
that are difficult to predict and many of which are outside of our control. Our
actual results and financial condition may differ materially from those indicated
in the forward-looking statements.Therefore, you should not rely on any of
these forward-looking statements. Important factors that could cause our actual
results and financial condition to differ materially from those indicated in the
forward-looking statements include, among others, the following:
—— We operate in a highly competitive industry, and if we are not able to
compete effectively, our business and operating results will be harmed;
—— The market for cloud-based services for health care information
technology may not develop substantially further or develop more
slowly than we expect, harming the growth of our business;
—— Changes in the health care industry could affect the demand
for our services, cause our existing contracts to terminate, and
negatively impact the process of negotiating further contracts;
—— If we do not continue to innovate and provide services that are
useful to clients and users, we may not remain competitive,
and our revenues and operating results could suffer;
—— We may be unable to adequately protect, and we may incur significant
costs in enforcing our intellectual property and other proprietary rights;
—— We may be sued by third parties for alleged
infringement of their proprietary rights;
—— Our business could be adversely affective if our
clients are not satisfied with our services;
—— We are a development stage company, with little operating
history and predictability as to future performance;
—— Our services and technology may not operate properly, which
could damage our reputation, give rise to claims against us, or
divert application of our resources from other purposes, any
of which could harm our business and operating results;
—— If our security measures are breached or fail or unauthorized access
if obtained to a client’s or member’s data, our services may be
perceived as not being secure, clients and members may curtail or
stop using our services and we may incur significant liabilities;
—— We rely on Internet infrastructure, bandwidth providers, data center
providers, other third parties, and our own systems for providing
services to our users, and any failure or interruption in the services
provided by these third parties by our own systems could expose
us to litigation and negatively impact our relationships with users
or clients, adversely affecting our brand and our business;
—— Government regulation of health care creates risks and challenges
with respect to our compliance efforts and our business strategies;
—— Potential health care reform and new regulatory requirements
placed on our software, services and content could impose increased
costs on us, delay or prevent our introduction of new services,
and impair the function or value of our existing services; and
—— Pressure from competitors with more resources may
limit our market share, profitability and growth.
Any forward-looking statement made by us in this investment brief is based
only on information currently available to us and speaks only as of the date on
which it is made. We undertake no obligation to publicly update any forward-
looking statement, whether written or oral, that may be made from time to time,
whether as a result of new information, future developments or otherwise.

14. Willowglade Technologies
Investment Brief 14
Contact
For More Information, Contact:
Thomas Carter
Capital Services Group, Inc.
thomas@capservegroup.com
760-845-7545